Guthrie wins $18k screening grant

Diabetic eye screening is one of those basic preventive things that sounds simple but often breaks in real life. Patients need the exam, but the specialist may be far away, the appointment may be months out, and a routine diabetes visit turns into one more thing to schedule later. Guthrie’s new $18,000 grant is small in budget terms, but the point is practical — it lets the health system put an AI-assisted retinal camera directly into primary care in Owego. That matters because diabetic retinopathy is treatable when caught early, and easy to miss when screening rates are low. (guthrie.org) ### What actually changed? Guthrie said on April 29 that Fidelis Care awarded it an $18,000 grant to deploy new diabetic vision-screening technology at Guthrie Owego Fifth Avenue. The money will buy an AEYE Health diagnostic camera, and the plan is to use it during routine primary care visits instead of forcing every patient to start with a separate eye appointment. (guthrie.org) ### Why does Owego matter here? Because the access gap is already visible in the numbers. Guthrie says only 19% of Medicaid patients with diabetes in the Owego service area are getting the annual retinal exams they’re supposed to have. In a rural setting, that usually means distance, scheduling friction, and specialist scarcity are doing real damage before anyone even gets to treatment. (guthrie.org) ### What does this camera actually do? The AEYE system takes retinal images and uses autonomous AI to flag diabetic retinopathy during a regular clinic visit. Basically, it moves the first pass of detection upstream. Instead of waiting for an ophthalmology slot just to learn whether something looks wrong, the primary care office can identify patients who need follow-up and refer the right people faster. (guthrie.org) ### Why is diabetic retinopathy the right target? Because this is exactly the kind of disease that punishes delay. Diabetic retinopathy can progress without obvious symptoms, but early detection can prevent or limit vision loss. That makes screening the bottleneck — not because treatment is unimportant, but because untreated disease often starts with people never getting in the door for the eye exam. (commonwealthfund.org) ### Why put it in primary care? Primary care is where diabetes management already happens. Guthrie’s own diabetes services include referral for dilated eye exams, so adding a screening camera at the clinic level turns that referral pathway into something mo(commonwealthfund.org)now on the route patients already take. (guthrie.org) ### Is $18,000 enough to matter? For a giant hospital buildout, no. For a targeted screening tool, yes. The win here is not scale by itself; it’s placement. A relatively modest grant can change how one clinic handles a common diabetes complication, and if screening rates rise from a 19% baseline, the effect could be outsized for a (guthrie.org)ectly from where the gap is today. (guthrie.org) ### What happens downstream? More screening usually means more identified cases, which means more follow-up demand for ophthalmology and retina care. That is the catch. Better front-end detection helps patients, but it also pushes work toward specialty services that then need capac(guthrie.org)ant plugs into an existing system rather than creating a brand-new one. (guthrie.org) ### Bottom line? This is a small rural health-tech grant with a very specific job: find diabetic eye disease earlier by making screening happen where patients already receive care. If Guthrie can lift exam rates in Owego from today’s very low level, the real value of the $18,000 will be measured less by the camera itself and more by how many missed cases stop being missed. (guthrie.org)